Hayek Kallen Investment Management cut its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,541 shares of the medical research company’s stock after selling 419 shares during the period. Thermo Fisher Scientific makes up 3.0% of Hayek Kallen Investment Management’s holdings, making the stock its 9th biggest holding. Hayek Kallen Investment Management’s holdings in Thermo Fisher Scientific were worth $4,456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Proficio Capital Partners LLC increased its position in shares of Thermo Fisher Scientific by 71.5% during the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after acquiring an additional 253 shares during the last quarter. Cribstone Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 8.7% during the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after acquiring an additional 50 shares during the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $113,000. Chicago Partners Investment Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $108,000. Finally, CWM LLC increased its position in shares of Thermo Fisher Scientific by 17.0% during the second quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 103 shares during the last quarter. Institutional investors and hedge funds own 83.36% of the company’s stock.

In other Thermo Fisher Scientific news, Director C Martin Harris sold 360 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total value of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares of the company’s stock, valued at $961,312.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Gregory J. Herrema sold 30,000 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $176.02, for a total transaction of $5,280,600.00. Following the completion of the sale, the senior vice president now directly owns 67,016 shares of the company’s stock, valued at approximately $11,796,156.32. The disclosure for this sale can be found here. Insiders sold 52,738 shares of company stock valued at $9,302,112 in the last ninety days. 0.49% of the stock is owned by corporate insiders.

A number of equities research analysts have weighed in on the stock. Jefferies Group LLC reiterated a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price target for the company in a research report on Thursday, September 7th. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley restated an “overweight” rating and issued a $220.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $202.21.

Thermo Fisher Scientific Inc (TMO) opened at 193.43 on Friday. The stock has a market cap of $75.46 billion, a P/E ratio of 33.70 and a beta of 1.05. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $194.30. The company has a 50-day moving average of $186.10 and a 200-day moving average of $173.62.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. During the same quarter last year, the company earned $2.03 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.45%.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/hayek-kallen-investment-management-sells-419-shares-of-thermo-fisher-scientific-inc-tmo/1611726.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.